A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2019-000532

Related search